Novel dibenzoylmethane derivative 2-allyl-1,3-diphenyl-1, 3-propanedione: a safe and effective topical treatment for melanoma.

IF 2.2 4区 医学 Q3 ONCOLOGY
Anti-Cancer Drugs Pub Date : 2025-09-01 Epub Date: 2025-06-17 DOI:10.1097/CAD.0000000000001730
Jefferson Viktor de Paula Barros Baeta, Maria Aparecida Braga Rocha E Oliveira, Fernada Rodrigues Nascimento, Marcos Rodrigo de Oliveira, Virgínia Ramos Pizziolo, Tiago Antônio de Oliveira Mendes, Gaspar Diaz-Muñoz, Anésia Aparecida Dos Santos, Marisa Alves Nogueira Diaz
{"title":"Novel dibenzoylmethane derivative 2-allyl-1,3-diphenyl-1, 3-propanedione: a safe and effective topical treatment for melanoma.","authors":"Jefferson Viktor de Paula Barros Baeta, Maria Aparecida Braga Rocha E Oliveira, Fernada Rodrigues Nascimento, Marcos Rodrigo de Oliveira, Virgínia Ramos Pizziolo, Tiago Antônio de Oliveira Mendes, Gaspar Diaz-Muñoz, Anésia Aparecida Dos Santos, Marisa Alves Nogueira Diaz","doi":"10.1097/CAD.0000000000001730","DOIUrl":null,"url":null,"abstract":"<p><p>This study investigated 2-allyl-1,3-diphenyl-1,3-propanedione (DPAP), a dibenzoylmethane derivative, as a potentially more effective and safer alternative to dacarbazine for melanoma treatment. The antitumor activity of DPAP was assessed through comprehensive in-vitro, in-silico, and in-vivo experiments. In-vitro assays evaluated DPAP's IC 50 values against melanoma cells, benchmarking its efficacy against dacarbazine. Molecular analyses explored apoptosis mechanisms, emphasizing the roles of FAS receptors and caspase pathways. In-silico absorption, distribution, metabolism, excretion, and toxicity analysis provided insights into DPAP's pharmacokinetic profile, including absorption, distribution, metabolism, and toxicity. In-vivo studies examined its effects on tumor volume, vascular endothelial growth factor (VEGF) levels, and the histopathology of the liver, kidney, and lymph nodes. DPAP demonstrated significantly enhanced antitumor activity, reflected by markedly lower IC 50 values compared with dacarbazine, underscoring its superior efficacy and specificity toward tumor cells. Molecular assays confirmed that DPAP induces apoptosis through modulation of FAS receptors and activation of caspase pathways. In-silico results revealed favorable pharmacokinetic properties, including high intestinal absorption and good tissue distribution, with no evidence of carcinogenic potential. Notably, in-vivo experiments showed that DPAP effectively reduced tumor volume and VEGF levels, while also preventing hepatotoxicity and nephrotoxicity. In addition, it inhibited the migration of tumor cells to lymph nodes. These findings position DPAP as a promising candidate for melanoma treatment, particularly as a topical therapeutic, offering enhanced efficacy and safety compared with existing treatments. DPAP is a promising candidate for melanoma treatment, particularly through topical application, offering a safer and more effective alternative to current treatments.</p>","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"607-621"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-Cancer Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CAD.0000000000001730","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This study investigated 2-allyl-1,3-diphenyl-1,3-propanedione (DPAP), a dibenzoylmethane derivative, as a potentially more effective and safer alternative to dacarbazine for melanoma treatment. The antitumor activity of DPAP was assessed through comprehensive in-vitro, in-silico, and in-vivo experiments. In-vitro assays evaluated DPAP's IC 50 values against melanoma cells, benchmarking its efficacy against dacarbazine. Molecular analyses explored apoptosis mechanisms, emphasizing the roles of FAS receptors and caspase pathways. In-silico absorption, distribution, metabolism, excretion, and toxicity analysis provided insights into DPAP's pharmacokinetic profile, including absorption, distribution, metabolism, and toxicity. In-vivo studies examined its effects on tumor volume, vascular endothelial growth factor (VEGF) levels, and the histopathology of the liver, kidney, and lymph nodes. DPAP demonstrated significantly enhanced antitumor activity, reflected by markedly lower IC 50 values compared with dacarbazine, underscoring its superior efficacy and specificity toward tumor cells. Molecular assays confirmed that DPAP induces apoptosis through modulation of FAS receptors and activation of caspase pathways. In-silico results revealed favorable pharmacokinetic properties, including high intestinal absorption and good tissue distribution, with no evidence of carcinogenic potential. Notably, in-vivo experiments showed that DPAP effectively reduced tumor volume and VEGF levels, while also preventing hepatotoxicity and nephrotoxicity. In addition, it inhibited the migration of tumor cells to lymph nodes. These findings position DPAP as a promising candidate for melanoma treatment, particularly as a topical therapeutic, offering enhanced efficacy and safety compared with existing treatments. DPAP is a promising candidate for melanoma treatment, particularly through topical application, offering a safer and more effective alternative to current treatments.

新型二苯甲酰甲烷衍生物2-烯丙基-1,3-二苯基-1,3-丙二酮:一种安全有效的黑色素瘤局部治疗药物。
本研究研究了2-烯丙基-1,3-二苯基-1,3-丙二酮(DPAP),一种二苯甲酰甲烷衍生物,作为一种潜在的更有效和更安全的替代达卡巴嗪治疗黑色素瘤的方法。通过体外、计算机和体内综合实验评估DPAP的抗肿瘤活性。体外实验评估了DPAP对黑色素瘤细胞的IC50值,对其对达卡巴嗪的疗效进行了基准测试。分子分析探讨凋亡机制,强调FAS受体和caspase途径的作用。硅吸收、分布、代谢、排泄和毒性分析提供了DPAP的药代动力学特征,包括吸收、分布、代谢和毒性。体内研究检查了其对肿瘤体积、血管内皮生长因子(VEGF)水平以及肝、肾和淋巴结的组织病理学的影响。与达卡巴嗪相比,DPAP的抗肿瘤活性显著增强,IC50值明显低于达卡巴嗪,表明其对肿瘤细胞具有更强的疗效和特异性。分子实验证实DPAP通过调节FAS受体和激活caspase通路诱导细胞凋亡。计算机模拟结果显示了良好的药代动力学特性,包括高肠道吸收和良好的组织分布,无致癌潜力的证据。值得注意的是,体内实验表明,DPAP能有效降低肿瘤体积和VEGF水平,同时还能预防肝毒性和肾毒性。此外,它还能抑制肿瘤细胞向淋巴结的迁移。这些发现使DPAP成为黑色素瘤治疗的一个有希望的候选者,特别是作为局部治疗,与现有治疗相比,具有更高的疗效和安全性。DPAP是一种很有前途的黑色素瘤治疗候选药物,特别是通过局部应用,提供了一种更安全、更有效的替代现有治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Anti-Cancer Drugs
Anti-Cancer Drugs 医学-药学
CiteScore
3.80
自引率
0.00%
发文量
244
审稿时长
3 months
期刊介绍: Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信